Screener
Aardvark Therapeutics, Inc. AARD Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Returns | ||||||
| Return on equity | -58.8%— | —— | —— | —— | —— | |
| Return on invested capital | -99.8%— | —— | —— | —— | —— | |
| Efficiency | ||||||
| Asset turnover | 0×— | 0×— | —— | —— | —— | |
| Liquidity | ||||||
| Current ratio | 8.1×-17.8× | 10.6×-4.4× | 12×— | 14×— | 25.9×— | |
| Leverage | ||||||
| Debt-to-equity | 0×0.0× | 0×— | 0×— | 0×— | 0×— | |
| Per Share | ||||||
| Book value per share | $3.99-65.1% | $5.43+140% | $5.64+149% | $6.31+159% | $11.42+223% | |
| Valuation | ||||||
| Market capitalization | $115.33M-65.4% | $285.77M— | $288.3M— | $341.81M— | —— | |
| Price / book | 1.3×-1.4× | 2.7×— | 2.4×— | 2.5×— | —— |
FAQ
- Where do Aardvark Therapeutics, Inc.'s ratios come from?
- Every ratio is computed from Aardvark Therapeutics, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.